
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix is expected to outperform the market due to its strong product portfolio, with DefenCath being a revolutionary catheter lock solution that has shown significant reduction in infection rates. Additionally, the positive data from the Ph.3 ReSPECT study further solidified Rezzayo's potential in the prophylaxis market, with a projected peak revenue of $220 million in 2034. With the potential for multiple label expansions in TPN, oncology, and pediatric hemodialysis, Cormedix has the potential for significant revenue growth in the future. Despite facing some challenges in commercial execution, competition, and potential label expansion approval, the overall positive outlook for Cormedix's products and potential for revenue diversification make it a promising investment opportunity.
Bears say
Cormedix is facing several significant challenges that could negatively impact their stock outlook in the future. These include potential delays or setbacks in the FDA approval process for their product Rezzayo in the prophylaxis indication, as well as potential enrollment challenges or negative results in clinical trials for DefenCath's label expansion into pediatric hemodialysis. The company also faces concentration and pricing risks with their primary customer and could experience a significant decline in stock valuation if their product fails to gain traction in the market.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares